GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (OTCPK:CPHI) » Definitions » ROE %

China Pharma Holding (China Pharma Holding) ROE % : -48.57% (As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is China Pharma Holding ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. China Pharma Holding's annualized net income for the quarter that ended in Mar. 2024 was $-3.82 Mil. China Pharma Holding's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $7.87 Mil. Therefore, China Pharma Holding's annualized ROE % for the quarter that ended in Mar. 2024 was -48.57%.

The historical rank and industry rank for China Pharma Holding's ROE % or its related term are showing as below:

CPHI' s ROE % Range Over the Past 10 Years
Min: -104.99   Med: -36.43   Max: -13.96
Current: -57.63

During the past 13 years, China Pharma Holding's highest ROE % was -13.96%. The lowest was -104.99%. And the median was -36.43%.

CPHI's ROE % is not ranked
in the Drug Manufacturers industry.
Industry Median: 4.2 vs CPHI: -57.63

China Pharma Holding ROE % Historical Data

The historical data trend for China Pharma Holding's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Pharma Holding ROE % Chart

China Pharma Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -104.99 -33.25 -48.48 -77.09 -52.43

China Pharma Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.50 -52.58 -59.48 -72.65 -48.57

Competitive Comparison of China Pharma Holding's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Pharma Holding's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's ROE % distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's ROE % falls into.



China Pharma Holding ROE % Calculation

China Pharma Holding's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-3.079/( (4.29+7.455)/ 2 )
=-3.079/5.8725
=-52.43 %

China Pharma Holding's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-3.824/( (7.455+8.292)/ 2 )
=-3.824/7.8735
=-48.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


China Pharma Holding  (OTCPK:CPHI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-3.824/7.8735
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.824 / 5.48)*(5.48 / 16.3295)*(16.3295 / 7.8735)
=Net Margin %*Asset Turnover*Equity Multiplier
=-69.78 %*0.3356*2.074
=ROA %*Equity Multiplier
=-23.42 %*2.074
=-48.57 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-3.824/7.8735
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-3.824 / -3.824) * (-3.824 / -3.664) * (-3.664 / 5.48) * (5.48 / 16.3295) * (16.3295 / 7.8735)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0437 * -66.86 % * 0.3356 * 2.074
=-48.57 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


China Pharma Holding ROE % Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


China Pharma Holding (China Pharma Holding) Business Description

Traded in Other Exchanges
N/A
Address
Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Executives
Ke Deng 10 percent owner NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216
Frank Waung officer: Chief Financial Officer 72 GREAT HILLS RD., SHORT HILLS NJ 07078
G Michael Bennett director 4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600
Yingwen Zhang director NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041
Baowen Dong director NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041
Heung Mei Tsui director, 10 percent owner FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX
Zhilin Li officer: President and CEO 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216
Jian Yang officer: Secretary NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216
Xinhua Wu officer: CFO 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216
George L Diamond 10 percent owner 174 FM 1830, ARGYLE TX 76226
David F Brigante 10 percent owner 174FM 1830, ARGYLE TX 76226
Marat Rosenberg 10 percent owner 17 FM 1830, ARGYLE TX 76226
Halter Financial Investments Lp 10 percent owner 174 FM 1830, ARGYLE TX 76226
Halter Financial Investments Gp Llc 10 percent owner 174 FM 1830, ARGYLE TX 76226
Timothy P Halter director, 10 percent owner, officer: CEO, President & CFO 174 FM 1830, ARGYLE TX 76226